Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model | Zendy

Stephen Tully | Zendy; Zeny Feng | Zendy; Kelly Grindrod | Zendy; Thomas McFarlane | Zendy; Kelvin Chan | Zendy; William Wong | Zendy

Open Access

Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model

Author(s) -

Stephen Tully,

Zeny Feng,

Kelly Grindrod,

Thomas McFarlane,

Kelvin Chan,

William Wong

Publication year - 2019

Publication title -

jco clinical cancer informatics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.188

H-Index - 12

ISSN - 2473-4276

DOI - 10.1200/cci.19.00086

Subject(s) - chimeric antigen receptor , medicine , lymphoma , refractory (planetary science) , chemotherapy , oncology , immunotherapy , cancer , biology , astrobiology

The development of chimeric antigen receptor (CAR) T cells has transformed oncology treatment, with the potential to cure certain cancers. Although shown to be effective in selected populations and studies, CAR T-cell technology requires considerable health care resources, which may lead to additional wait times to access this type of treatment in future. The objective of our study was to estimate the potential impact of increasing wait times on CAR T-cell therapy effectiveness compared with standard chemotherapy for patients with relapsed/refractory diffuse large B-cell lymphoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research